Back to Search
Start Over
Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease.
- Source :
-
Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2019 Mar; Vol. 49 (6), pp. 664-680. Date of Electronic Publication: 2019 Feb 08. - Publication Year :
- 2019
-
Abstract
- Background: Biological therapy is currently widely used to treat IBD. Infliximab, adalimumab and golimumab are currently licensed anti-TNF therapies. Biosimilar anti-TNF monoclonal antibodies are increasingly used. Anti-TNF therapies are widely used and their adverse effects are well characterised, and may cause significant morbidity and mortality in a small proportion of exposed patients. Gastroenterologists need to understand the mechanisms for these effects, recognise these swiftly and manage such events appropriately.<br />Aim: To cover the range of potential adverse reactions as a result of biologic therapy and specifically management of these events.<br />Methods: A Medline and Pubmed search was undertaken. Search terms included were "anti-TNF," "infliximab" or "adalimumab" or "golimumab" combined with the keywords "ulcerative colitis" or "Crohn's disease" or "inflammatory bowel disease" and then narrowed to articles containing the keywords "complications," "side effects" or "adverse events" or "safety profile." International guidelines were also reviewed where relevant.<br />Results: Adverse events discussed in this review include infusion reactions, blood disorders and infections (including bacterial, viral, fungal and opportunistic infections) as well as autoimmune, dermatological disorders, cardiac and neurological conditions. Malignancies including solid organ, haematological and those linked to viral disease are discussed.<br />Conclusions: Anti-TNF therapy has wide-ranging effects on the immune system resulting in a spectrum of potential adverse events in a small proportion of patients. Research advances are improving the understanding, recognition and management of these adverse events.<br /> (© 2019 John Wiley & Sons Ltd.)
- Subjects :
- Adalimumab therapeutic use
Anemia chemically induced
Anemia metabolism
Antibodies, Monoclonal therapeutic use
Autoimmune Diseases chemically induced
Autoimmune Diseases metabolism
Humans
Inflammatory Bowel Diseases metabolism
Infliximab therapeutic use
Tumor Necrosis Factor-alpha metabolism
Adalimumab adverse effects
Antibodies, Monoclonal adverse effects
Disease Management
Inflammatory Bowel Diseases drug therapy
Infliximab adverse effects
Tumor Necrosis Factor-alpha antagonists & inhibitors
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2036
- Volume :
- 49
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Alimentary pharmacology & therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 30735257
- Full Text :
- https://doi.org/10.1111/apt.15097